(19)
(11) EP 3 460 064 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.03.2024 Bulletin 2024/12

(45) Mention of the grant of the patent:
07.02.2024 Bulletin 2024/06

(21) Application number: 18183738.6

(22) Date of filing: 12.03.2012
(51) International Patent Classification (IPC): 
C12N 15/87(2006.01)
A61K 48/00(2006.01)
A61P 35/00(2006.01)
 C12N 15/11(2006.01)
A61P 43/00(2006.01)
A61K 31/7115(2006.01)
(52) Cooperative Patent Classification (CPC):
A01K 67/0276; A61K 48/005; C12N 15/111; A01K 2207/05; A01K 2217/075; A01K 2227/105; A01K 2267/03; A01K 2267/0393; C12N 2310/11; C12N 2310/14; C12N 2800/30; A61K 31/7115; A61K 31/4745; A61K 31/513; A61K 31/517; A61K 31/519; A61K 31/555; A61K 31/7068; A61L 31/10; A61L 31/16; A61L 2300/258; A61K 38/1866; A61P 1/18; A61P 11/00; A61P 13/12; A61P 21/00; A61P 21/04; A61P 29/00; A61P 35/00; A61P 37/02; A61P 37/06; A61P 43/00; A61P 9/00; A61P 9/04; A61P 9/06; A61P 9/10; A61P 9/12; A61K 33/243
 
C-Sets:
  1. A61K 31/4745, A61K 2300/00;
  2. A61K 31/555, A61K 2300/00;
  3. A61K 31/519, A61K 2300/00;
  4. A61K 31/517, A61K 2300/00;
  5. A61K 31/7115, A61K 2300/00;
  6. A61K 31/7068, A61K 2300/00;
  7. A61K 31/513, A61K 2300/00;
  8. A61K 33/24, A61K 2300/00;

(54)

EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA)

EFFIZIENTE IN-VIVO-PROTEINEXPRESSION MITTELS MODIFIZIERTER RNA (MOD-RNA)

EXPRESSION PROTÉIQUE EFFICACE IN VIVO À L'AIDE D'ARN MODIFIÉ (MOD-ARN)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 03.04.2011 US 201161471166 P
04.04.2011 US 201161471584 P

(43) Date of publication of application:
27.03.2019 Bulletin 2019/13

(62) Application number of the earlier application in accordance with Art. 76 EPC:
12767300.2 / 2694660

(73) Proprietors:
  • The General Hospital Corporation d/b/a Massachusetts General Hospital
    Boston, MA 02114 (US)
  • The Children's Medical Center Corporation
    Boston, MA 02115 (US)

(72) Inventors:
  • CHIEN, Kenneth R.
    Cambridge, MA 02138 (US)
  • PTASZEK, Leon M.
    Newton, MA 02461 (US)
  • LUI, Oi Lan
    Boston, MA 02114 (US)
  • ZANGI, Lior
    New York, NY 10028 (US)
  • EBINA, Wataru
    New York, New York 10017 (US)
  • ROSSI, Derrick J.
    Newton, MA 02459 (US)

(74) Representative: Kehoe, Laura Ellen et al
Keltie LLP No.1 London Bridge
London SE1 9BA
London SE1 9BA (GB)


(56) References cited: : 
WO-A1-2009/127230
WO-A2-2010/144678
 WO-A2-2007/024708
CA-A1- 2 769 670
   
  • LIOR ZANGI ET AL: "Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction", NATURE BIOTECHNOLOGY, vol. 31, no. 10, 1 October 2013 (2013-10-01), pages 898-907, XP055145576, ISSN: 1087-0156, DOI: 10.1038/nbt.2682
  • KATHY O. LUI ET AL: "Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA", STEM CELL RESEARCH, vol. 13, no. 3, 1 November 2014 (2014-11-01), pages 693-704, XP055532693, NL ISSN: 1873-5061, DOI: 10.1016/j.scr.2014.06.007
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).